Phentermine vs. GLP-1 Medications: What’s the Difference and Which May Be Right for You?

More people are living with obesity than ever before. This also means more people are exploring medical weight-loss options. As such, phentermine and GLP-1 medications tend to come up a lot in research and conversations around weight loss medications. 

Both are prescription physician-led tools for weight loss. While phentermine has been around since the 1950s, GLP-1 medications offer a newer alternative. But is one better than the other? If you’ve been taking phentermine, should you consider switching to GLP-1s?

Below, we outline what each medication is, how they compare side by side, including GLP-1 vs stimulants like phentermine, what the long-term outlook looks like, and how to think about which may be right for you.

‍

What Is Phentermine and How Does It Work?

Phentermine is an FDA-approved prescription appetite suppressant that has been used for weight loss since 1959, making it one of the oldest weight loss medications still prescribed today. 

It belongs to a class of drugs called anorectics (medications that reduce appetite) and is classified by the United States Drug Enforcement Administration (DEA) as a Schedule IV controlled substance, meaning it has recognized medical use but also some potential for dependence.

So, how does it work exactly?

Phentermine stimulates the central nervous system (CNS) similarly to amphetamines, primarily triggering the release of norepinephrine in the brain. This signal tells the hypothalamus to reduce appetite, and it can also slightly increase heart rate and blood pressure. 

Put simply, it works by signaling your brain that you’re not hungry, similar to the body’s natural “fight or flight” response. 

However, phentermine is approved only for short-term use, typically up to 12 weeks, and is generally prescribed for adults with a BMI of 30 or higher, or 27 or higher when paired with a weight-related condition such as diabetes, high cholesterol, or controlled high blood pressure.

‍

Common Forms and Dosing

Phentermine is available as tablets and capsules. Adipex-P® is the most recognized brand at the standard 37.5 mg strength and comes in both tablet and capsule form. Meanwhile, Lomaira® is a lower-dose 8 mg tablet taken three times daily, about 30 minutes before meals.

Standard dosing for the larger strengths is typically 15 mg, 30 mg, or 37.5 mg once daily before breakfast. Dosing is always physician-directed and should never be self-adjusted.

‍

What Are GLP-1 Medications and How Do They Work?

GLP-1 medications are a newer class of drugs that mimic the glucagon-like peptide-1 hormone. This hormone is produced by the gut after eating, and helps regulate appetite, slow digestion, and support steadier blood sugar levels. For a deeper look at how semaglutide works, you can explore additional educational resources that break down its mechanism in more detail.

Unlike phentermine, GLP-1 medications don’t rely on stimulating the nervous system. Instead, they work through several pathways at once, including:

• Slowing how quickly the stomach empties (which keeps you fuller longer)
• Reducing appetite signals in the brain
• Supporting insulin release
• Blunting glucagon (a hormone that raises blood sugar)

Tirzepatide goes a step further by acting on a second hormone pathway (GIP) in addition to GLP-1, which may further support metabolic regulation. 

It’s likely you’re already familiar with some types of these medications, including semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®). Most of these are administered as once-weekly subcutaneous injections, though some are daily. Additionally, oral semaglutide (Rybelsus®) is approved for type 2 diabetes. 

Compounded versions of semaglutide and tirzepatide are also available through licensed telehealth providers and compounding pharmacies. Yet, compounded GLP-1 medications may only be prescribed by a licensed provider and prepared by a compounding pharmacy when a clinically significant difference is identified for an individual patient. These medications are not FDA-approved and may vary in formulation and availability. 

‍

FDA Approval and Intended Use

Wegovy® (semaglutide 2.4 mg) and Zepbound® (tirzepatide) are specifically FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. 

Ozempic® and Mounjaro® are FDA-approved for the management of type 2 diabetes (with Ozempic® also approved to reduce cardiovascular risk in T2D patients), but both are sometimes prescribed off-label at a provider’s discretion. 

Unlike phentermine, GLP-1 medications are approved for long-term, chronic use. 

‍

Phentermine vs. GLP-1 Medications: A Side-by-Side Comparison

Here’s a side-by-side weight loss drug comparison that includes how they’re taken, how long they’re used, how they work, and side effects.

‍

Mechanism of Action

Phentermine essentially overrides hunger signals by stimulating the central nervous system, which is why people often feel its effects quickly and why side effects like jitteriness or sleep disruption can appear early. 

GLP-1 medications, on the other hand, work with the body’s own gut-brain hormonal system. The experience tends to feel less stimulating and more like a gradual change in appetite and fullness.

‍

Duration of Use

Phentermine is approved for short-term treatment, typically capped at 12 weeks, because tolerance may develop and the risk of dependence increases with prolonged use. 

GLP-1 medications, by contrast, are designed for long-term use and are often continued indefinitely as part of an ongoing weight management plan. 

In fact, these clinical guidelines reflect the growing recognition of obesity as a chronic condition that benefits from sustained treatment, as opposed to a problem that needs to be solved in a matter of weeks.

‍

Weight Loss Efficacy

Studies on phentermine have shown average weight loss of approximately 5% of body weight over 12 weeks when combined with diet and exercise. 

For GLP-1 medications, the numbers are larger and are measured over longer time frames. The STEP 1 trial of semaglutide found participants lost an average of about 14.9% of body weight over 68 weeks. The SURMOUNT-1 trial of tirzepatide reported average reductions of up to 20.9% of body weight at the highest dose over 72 weeks. As with any medication, individual results may vary based on dose, duration, lifestyle, and overall health.

‍

Safety Profile and Side Effects

Phentermine may cause:

• Increased heart rate
• Elevated blood pressure
• Insomnia
• Dry mouth
• Restlessness
• Headaches
• Dizziness

These effects tend to surface early in treatment. As a Schedule IV controlled substance, it also carries recognized risks of misuse, dependence, and withdrawal.

GLP-1 medications may cause gastrointestinal symptoms, such as:

• Nausea
• Vomiting
• Diarrhea
• Constipation

These tend to happen most often when increasing doses, but usually improve over time. 

For more context on weight loss medication safety, readers can review additional educational resources before discussing options with a licensed provider.

More serious but rare risks of GLP-1s include pancreatitis. GLP-1 medications also carry a boxed warning for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2). 

‍

Cardiovascular Considerations

Since phentermine is a stimulant, it raises heart rate and blood pressure and is contraindicated in patients with existing heart disease, uncontrolled hypertension, or a history of stroke. 

Certain FDA-approved GLP-1 medications, by contrast, have shown cardiovascular benefits in clinical trials. The SUSTAIN-6 trial of semaglutide demonstrated a reduction in major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease. 

For patients whose health history includes cardiovascular concerns, this difference often plays a major role in what a provider may recommend.

‍

Eligibility and Contraindications

As stated above, phentermine may not be appropriate for people with cardiovascular disease, uncontrolled high blood pressure, hyperthyroidism, glaucoma, a history of substance misuse, or anyone pregnant or breastfeeding. It’s also generally not recommended for adults 65 and older, and it shouldn’t be taken within 14 days of an MAO inhibitor.

GLP-1 medications, on the other hand, may not be appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, severe gastrointestinal conditions like gastroparesis, or anyone pregnant or breastfeeding. 

Ultimately, a licensed healthcare provider who reviews your full medical history, current medications, and overall health can help you make the best decision for you.

‍

Long-Term Outcomes and Weight Regain

So, will you regain the weight lost with these medications? This depends on a few factors and the specific medication.

With phentermine, most patients discontinue treatment within 12 weeks because of its current approved usage by the FDA. Studies report that weight regain after stopping phentermine is common, since the underlying hormonal and metabolic drivers of obesity are no longer being addressed. Without continued treatment or significant lifestyle changes, the appetite suppression effect ends when the medication does.

When comparing phentermine vs semaglutide, the STEP 1 trial reported that participants who stopped semaglutide medication after 68 weeks regained roughly two-thirds of their lost weight within one year. However, GLP-1 medications, such as semaglutide, are approved for long-term use, so many patients can continue this treatment as part of a sustained weight management plan (an option that may not be available with phentermine).

With that said, however, both medications work best alongside ongoing lifestyle support; neither is a permanent fix on its own.

‍

Which May Be Right for You?

Choosing between GLP-1 medications and phentermine depends on your health history, preferences, and what a licensed healthcare provider determines is appropriate for your individual needs.

GLP-1 medications may be considered for individuals looking for a longer-term approach to weight management, particularly when combined with lifestyle changes and ongoing medical supervision. In some cases, providers may consider these options for individuals with a body mass index (BMI) of 30 or higher, or 27 or higher with weight-related health conditions—you can calculate your BMI to better understand where you fall.

A provider may consider phentermine for short-term use in certain patients, particularly when a stimulant-based approach is appropriate, and no cardiovascular contraindications are present.

For individuals who prefer not to use injections or who may be transitioning off GLP-1 therapy, there are also oral weight loss program options that a provider may consider as part of a broader, medically guided plan.

The best approach depends on your goals, medical history, and how your body responds to treatment, which is why working with a licensed provider is an important part of the process.

‍

How Eden Supports GLP-1 Weight Loss

If treatment options may be appropriate for you, Eden can help coordinate your care. Eden’s platform is 100% online, available in all 50 states, and doesn’t require insurance.

It all begins with a quick online intake. From there, you’ll be connected with a licensed healthcare provider via telehealth who will review your health history, goals, and lifestyle to determine whether treatment is appropriate. 

To learn more about your options, you can explore Eden’s GLP-1 weight loss program, where licensed providers determine whether treatment may be appropriate as part of a broader care plan.

Through Eden, you may have access to features such as provider messaging and follow-up care. Eden offers transparent pricing with no hidden fees, and you can use FSA/HSA funds for eligible expenses.